We are live on ! Find out more
KXA

KPCB XIII Associates Portfolio holdings

AUM $186M
1-Year Est. Return 11.23%
This Fund
S&P 500
This Quarter Est. Return
+44.98%
1 Year Est. Return
-11.23%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$619M
AUM Growth
–
Cap. Flow
+$492M
Cap. Flow %
79.47%
Top 10 Hldgs %
100%
Holding
4
New
4
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PGNY icon
Progyny
PGNY
+$361M
2
LUNG icon
Pulmonx
LUNG
+$69.6M
3
EPZM
Epizyme, Inc
EPZM
+$47.3M
4
TMDX icon
Transmedics
TMDX
+$13.8M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGNY icon
1
Progyny
PGNY
$2.44B
$470M 76.02%
+11,093,696
New +$361M
LUNG icon
2
Pulmonx
LUNG
$49.4M
$88.3M 14.27%
+1,421,386
New +$69.6M
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$41.7M 6.74%
+3,838,166
New +$47.3M
TMDX icon
4
Transmedics
TMDX
$2.5B
$18.4M 2.97%
+932,221
New +$13.8M

Similar funds

BC
Bullfrog Capital Palo Alto, California $191M AUM 19.3% 1-Year Est. Return
CC
Claybrook Capital Wellesley, Massachusetts $175M AUM 10.74% 1-Year Est. Return
BAG
Briggs Advisory Group Lincoln, Rhode Island $175M AUM 16.29% 1-Year Est. Return
SWA
Sutton Wealth Advisors Tampa, Florida $203M AUM 20.54% 1-Year Est. Return
DLG
Daniel L. Goodwin $207M AUM 22.03% 1-Year Est. Return
NFAM
North Fourth Asset Management Englewood Cliffs, New Jersey $164M AUM 43.6% 1-Year Est. Return
RCGI
Ribbit Capital GP III Palo Alto, California $211M AUM 51.22% 1-Year Est. Return
TA
Trellis Advisors Ellensburg, Washington $219M AUM 17.82% 1-Year Est. Return

KPCB XIII Associates's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for KPCB XIII Associates, which disclosed 4 positions worth $619M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Progyny: 11,093,696 shares worth $470M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • KPCB XIII Associates's largest Q4 2020 buy was Progyny: 11,093,696 shares worth $470M.
  • KPCB XIII Associates's ten largest holdings make up 100% of its $619M portfolio in Q4 2020.
  • KPCB XIII Associates disclosed 4 positions in Q4 2020, its first 13F filing on record.

Based on KPCB XIII Associates's 13F filing for Q4 2020, filed 16 Feb 2021.